These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283 [TBL] [Abstract][Full Text] [Related]
4. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma. Pellegatta S; Valletta L; Corbetta C; Patanè M; Zucca I; Riccardi Sirtori F; Bruzzone MG; Fogliatto G; Isacchi A; Pollo B; Finocchiaro G Acta Neuropathol Commun; 2015 Jan; 3():4. PubMed ID: 25849072 [TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. Kamran N; Kadiyala P; Saxena M; Candolfi M; Li Y; Moreno-Ayala MA; Raja N; Shah D; Lowenstein PR; Castro MG Mol Ther; 2017 Jan; 25(1):232-248. PubMed ID: 28129117 [TBL] [Abstract][Full Text] [Related]
6. Zinc Finger MYND-Type Containing 8 (ZMYND8) Is Epigenetically Regulated in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma to Promote Radioresistance. Carney SV; Banerjee K; Mujeeb A; Zhu B; Haase S; Varela ML; Kadiyala P; Tronrud CE; Zhu Z; Mukherji D; Gorla P; Sun Y; Tagett R; Núñez FJ; Luo M; Luo W; Ljungman M; Liu Y; Xia Z; Schwendeman A; Qin T; Sartor MA; Costello JF; Cahill DP; Lowenstein PR; Castro MG Clin Cancer Res; 2023 May; 29(9):1763-1782. PubMed ID: 36692427 [TBL] [Abstract][Full Text] [Related]
7. SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors. Wang X; Chen Z; Xu J; Tang S; An N; Jiang L; Zhang Y; Zhang S; Zhang Q; Shen Y; Chen S; Lan X; Wang T; Zhai L; Cao S; Guo S; Liu Y; Bi A; Chen Y; Gai X; Duan Y; Zheng Y; Fu Y; Li Y; Yuan L; Tong L; Mo K; Wang M; Lin SH; Tan M; Luo C; Chen Y; Liu J; Zhang Q; Li L; Huang M Cell Res; 2022 Jul; 32(7):638-658. PubMed ID: 35459936 [TBL] [Abstract][Full Text] [Related]
8. Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability. Thomas D; Wu M; Nakauchi Y; Zheng M; Thompson-Peach CAL; Lim K; Landberg N; Köhnke T; Robinson N; Kaur S; Kutyna M; Stafford M; Hiwase D; Reinisch A; Peltz G; Majeti R Cancer Discov; 2023 Feb; 13(2):496-515. PubMed ID: 36355448 [TBL] [Abstract][Full Text] [Related]
9. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies. Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251 [TBL] [Abstract][Full Text] [Related]
10. To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma. Bhavya B; Anand CR; Madhusoodanan UK; Rajalakshmi P; Krishnakumar K; Easwer HV; Deepti AN; Gopala S Cell Mol Neurobiol; 2020 Jan; 40(1):53-63. PubMed ID: 31485826 [TBL] [Abstract][Full Text] [Related]
11. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-α. Kohanbash G; McKaveney K; Sakaki M; Ueda R; Mintz AH; Amankulor N; Fujita M; Ohlfest JR; Okada H Cancer Res; 2013 Nov; 73(21):6413-23. PubMed ID: 24030977 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies. Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098 [TBL] [Abstract][Full Text] [Related]
13. Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective. Ma T; Zou F; Pusch S; Xu Y; von Deimling A; Zha X J Med Chem; 2018 Oct; 61(20):8981-9003. PubMed ID: 29847930 [TBL] [Abstract][Full Text] [Related]
14. Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results. Picca A; Finocchiaro G Curr Opin Oncol; 2022 Nov; 34(6):653-660. PubMed ID: 36000367 [TBL] [Abstract][Full Text] [Related]
15. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. Mondesir J; Willekens C; Touat M; de Botton S J Blood Med; 2016; 7():171-80. PubMed ID: 27621679 [TBL] [Abstract][Full Text] [Related]
16. Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma. Wang QX; Zhang PY; Li QQ; Tong ZJ; Wu JZ; Yu SP; Yu YC; Ding N; Leng XJ; Chang L; Xu JG; Sun SL; Yang Y; Li NG; Shi ZH Eur J Med Chem; 2023 Sep; 257():115464. PubMed ID: 37235998 [TBL] [Abstract][Full Text] [Related]
17. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers. Gunn K; Myllykoski M; Cao JZ; Ahmed M; Huang B; Rouaisnel B; Diplas BH; Levitt MM; Looper R; Doench JG; Ligon KL; Kornblum HI; McBrayer SK; Yan H; Duy C; Godley LA; Koivunen P; Losman JA Cancer Discov; 2023 Jun; 13(6):1478-1497. PubMed ID: 36847506 [TBL] [Abstract][Full Text] [Related]
18. Recent advances of IDH1 mutant inhibitor in cancer therapy. Tian W; Zhang W; Wang Y; Jin R; Wang Y; Guo H; Tang Y; Yao X Front Pharmacol; 2022; 13():982424. PubMed ID: 36091829 [TBL] [Abstract][Full Text] [Related]
19. Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma. Peters KB; Alford C; Heltemes A; Savelli A; Landi DB; Broadwater G; Desjardins A; Johnson MO; Low JT; Khasraw M; Ashley DM; Friedman HS; Patel MP Neurooncol Pract; 2024 Apr; 11(2):199-204. PubMed ID: 38496920 [TBL] [Abstract][Full Text] [Related]
20. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]